Jasper Therapeutics, Inc. (JSPR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Jasper Therapeutics, Inc. (JSPR) trades at $0.48 with AI Score 27/100 (Grade F). Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutic agents for hematopoietic stem cell transplantation and gene therapies. Market cap: $7.72M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026JSPR stock analysis for 2026: Analysts have set a consensus price target of $3.00 for Jasper Therapeutics, Inc., suggesting 531.2% upside from the current price of $0.48. The AI MoonshotScore is 27/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
JSPR: 1/1 perspectives are bearish.
How is this calculated? →Jasper Therapeutics, Inc. (JSPR) Healthcare & Pipeline Overview
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering therapeutic agents for hematopoietic stem cell transplantation and gene therapies. Their lead product, JSP191, aims to improve stem cell therapy outcomes by clearing hematopoietic stem cells from bone marrow, positioning them within the evolving landscape of cell and gene therapy.
What Is the Investment Thesis for JSPR?
Jasper Therapeutics, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its lead product candidate, JSP191. JSP191's clinical development as a conditioning antibody for hematopoietic stem cell transplantation and gene therapy represents a significant value driver. Successful clinical trials and subsequent regulatory approval could lead to substantial revenue generation. The company's focus on engineered hematopoietic stem cells further diversifies its pipeline and addresses limitations in current transplantation methods. However, the company's market capitalization of $7.72M reflects the inherent risks associated with clinical-stage biotechnology companies, including potential clinical trial failures, regulatory hurdles, and competition from established players. The company's beta of 3.20 indicates high volatility, requiring investors to carefully consider their risk tolerance. Upcoming clinical trial results for JSP191 will be a critical catalyst to watch.
Based on FMP financials and quantitative analysis
JSPR Key Highlights
- Jasper Therapeutics is a clinical-stage biotechnology company focused on hematopoietic stem cell transplantation and gene therapies.
- The lead product candidate, JSP191, is in clinical development as a conditioning antibody.
- The company is developing engineered hematopoietic stem cell product candidates.
- Jasper Therapeutics is based in Redwood City, California.
- The company has a market capitalization of $7.72M and a beta of 3.20.
Who Are JSPR's Competitors?
JSPR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| VRTX Vertex Pharmaceuticals Incorporated | $529.59 | +0.29% | 135B | 99 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JSPR's Key Strengths?
- Innovative technology platform for stem cell engineering.
- Lead product candidate, JSP191, in clinical development.
- Experienced management team with expertise in biotechnology.
- Focus on a growing market with unmet medical needs.
What Are JSPR's Weaknesses?
- Clinical-stage company with no currently approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
- High cash burn rate associated with research and development.
What Could Drive JSPR Stock Higher?
- Clinical trial results for JSP191 in stem cell transplantation.
- Regulatory submissions for JSP191.
- Development of engineered hematopoietic stem cell product candidates.
- Strategic partnerships and collaborations.
What Are the Key Risks for JSPR?
- Financial-distress signal — its Altman Z-Score of -28.81 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for JSP191.
- Regulatory delays or non-approval of JSP191.
- Competition from established pharmaceutical companies.
- High cash burn rate and need for additional financing.
- Dependence on key personnel and intellectual property.
What Are the Growth Opportunities for JSPR?
- Expansion of JSP191 into New Indications: Jasper Therapeutics has the opportunity to expand the use of JSP191 beyond its current clinical focus. Exploring its application in other hematological malignancies or autoimmune diseases could significantly broaden its market potential. The market for conditioning agents in stem cell transplantation is estimated to grow as stem cell therapies become more prevalent. This expansion could occur within the next 3-5 years, contingent on successful clinical trials and regulatory approvals.
- Development of Engineered Hematopoietic Stem Cells: The company's efforts to develop engineered hematopoietic stem cells represent a significant growth opportunity. These engineered cells could overcome limitations of allogeneic and autologous gene-edited stem cell grafts, potentially leading to more successful transplantation outcomes. The market for gene-edited cell therapies is rapidly expanding, driven by advancements in gene editing technologies. This development could materialize in the next 5-7 years, pending further research and clinical validation.
- Strategic Partnerships and Collaborations: Jasper Therapeutics can pursue strategic partnerships and collaborations with other biotechnology companies or academic institutions to accelerate the development and commercialization of its product candidates. Collaborations can provide access to new technologies, funding, and expertise. The biotechnology industry is characterized by numerous partnerships aimed at sharing resources and mitigating risks. Such partnerships could be established within the next 1-2 years.
- Geographic Expansion: Jasper Therapeutics has the opportunity to expand its geographic reach beyond the United States. Entering European or Asian markets could significantly increase its potential customer base. The global market for stem cell transplantation is growing, with increasing demand in emerging economies. This expansion could occur in the next 3-5 years, contingent on regulatory approvals and market access strategies.
- Advancements in Manufacturing Processes: Improving the efficiency and scalability of its manufacturing processes can reduce costs and increase the availability of its products. Investing in advanced manufacturing technologies can provide a competitive advantage. The biotechnology industry is constantly seeking ways to optimize manufacturing processes to improve profitability. These advancements could be implemented within the next 2-3 years.
What Opportunities Does JSPR Have?
- Expansion of JSP191 into new indications.
- Development of engineered hematopoietic stem cells.
- Strategic partnerships and collaborations.
- Geographic expansion into international markets.
What Threats Does JSPR Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Changes in healthcare reimbursement policies.
What Are JSPR's Competitive Advantages?
- Proprietary technology and intellectual property related to JSP191 and engineered stem cells.
- Clinical data supporting the safety and efficacy of its product candidates.
- Expertise in stem cell biology and transplantation.
- Strong relationships with key opinion leaders in the field.
What Does JSPR Do?
Jasper Therapeutics, Inc., established to advance the field of stem cell transplantation and gene therapy, is a clinical-stage biotechnology company dedicated to developing innovative therapeutic solutions. The company's primary focus is on overcoming the limitations associated with hematopoietic stem cell transplantation, a procedure used to treat various blood cancers and genetic disorders. Jasper Therapeutics is headquartered in Redwood City, California. Their lead product candidate, JSP191, is a conditioning antibody designed to clear hematopoietic stem cells from the bone marrow of patients before they undergo allogeneic stem cell therapy or stem cell gene therapy. This conditioning process is crucial for creating space in the bone marrow, allowing the transplanted or gene-modified stem cells to engraft and proliferate. In addition to JSP191, Jasper Therapeutics is developing engineered hematopoietic stem cell product candidates. These engineered cells are designed to address the challenges of graft rejection and improve the overall success of stem cell transplantation. The company's research and development efforts are centered on expanding the accessibility and efficacy of stem cell transplantation and ex vivo gene therapy, a technique involving the genetic manipulation of cells outside the body before transplantation. By focusing on both conditioning agents and stem cell engineering, Jasper Therapeutics aims to provide comprehensive solutions for patients in need of stem cell-based therapies.
What Products and Services Does JSPR Offer?
- Develops therapeutic agents for hematopoietic stem cell transplantation.
- Focuses on conditioning agents to prepare patients for stem cell therapy.
- Engineers stem cells to improve transplantation outcomes.
- Conducts clinical trials to evaluate the safety and efficacy of its products.
- Aims to expand the use of stem cell transplantation and gene therapy.
- Develops JSP191, a conditioning antibody in clinical development.
How Does JSPR Make Money?
- Develops and patents therapeutic agents for stem cell transplantation and gene therapy.
- Outlicenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing agreements, milestone payments, and royalties.
- Focuses on research and development to create innovative products.
What Industry Does JSPR Operate In?
Jasper Therapeutics operates within the biotechnology industry, specifically targeting the hematopoietic stem cell transplantation and gene therapy market. This market is driven by the increasing prevalence of blood cancers, genetic disorders, and the growing demand for personalized medicine. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing similar therapies. Jasper Therapeutics aims to differentiate itself through its focus on conditioning agents and stem cell engineering, seeking to improve the safety and efficacy of stem cell transplantation. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Who Are JSPR's Key Customers?
- Hospitals and transplant centers that perform stem cell transplantations.
- Patients with blood cancers and genetic disorders who require stem cell therapy.
- Pharmaceutical companies that license or partner with Jasper Therapeutics.
- Research institutions and academic centers involved in stem cell research.
FY2026 estForward Outlook
Wall Street analysts project Jasper Therapeutics, Inc. revenue of about $1.1M for fiscal 2026, with EPS near $-1.07. The estimate reflects 5 contributing analysts.
F-Score 0/9Financial Health
Jasper Therapeutics, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.81 places it in the distress zone, a signal of elevated financial risk.
Jasper Therapeutics, Inc. (JSPR) Valuation Context
Valued at $7.72M, JSPR is classified as a micro-cap stock. Relative to its peer group, JSPR's quantitative score of 27/100 is below the peer average of 88/100.
JSPR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying activity suggests confidence in Jasper's future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively with discussions around innovative treatments gaining traction, reflecting optimism about product pipelines.
- The company has been actively engaging with investors, fostering a transparent relationship that enhances trust and interest in its developments.
- Recent collaborations with research institutions have positioned Jasper as a key player in the biotech space, attracting attention from both the market and potential partners.
Bear Case
- Concerns have been raised regarding the lengthy timelines for clinical trials, which could delay potential revenue generation and impact investor sentiment.
- Market perception is cautious, with some analysts questioning the scalability of Jasper's technologies in a competitive landscape.
- Recent bearish community discussions highlight worries about funding and financial sustainability, suggesting that investors are wary of cash flow challenges.
- Increased scrutiny from regulatory bodies has led to uncertainty about approval timelines, which may dampen enthusiasm among potential investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
JSPR Latest News
-
Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3
benzinga · Jun 9, 2026
-
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate
benzinga · Jun 5, 2026
-
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
zacks.com · Jun 3, 2026
-
Sector Update: Healthcare Stocks Fall Late Afternoon
MT Newswires · Jun 1, 2026
JSPR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JSPR.
Price Targets
Consensus target: $3.00
JSPR MoonshotScore
What does this score mean?
The MoonshotScore rates JSPR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
Sector Update: Healthcare Stocks Fall Late Afternoon
Leadership: Jeetinder Singh Mahal
CEO
Jeetinder Singh Mahal is the Chief Executive Officer of Jasper Therapeutics, Inc. He brings extensive experience in the biotechnology industry, with a focus on developing and commercializing innovative therapies. Prior to joining Jasper Therapeutics, he held leadership positions at various pharmaceutical and biotechnology companies, where he oversaw research and development, clinical operations, and commercial strategy. He has a strong track record of driving growth and creating value for shareholders.
Track Record: Under Jeetinder Singh Mahal's leadership, Jasper Therapeutics has advanced the clinical development of JSP191 and expanded its pipeline of engineered hematopoietic stem cell product candidates. He has focused on building a strong team and securing strategic partnerships to support the company's growth. His leadership has been instrumental in navigating the challenges of clinical-stage drug development and positioning Jasper Therapeutics for future success.
What Investors Ask About Jasper Therapeutics, Inc. (JSPR) — Healthcare
What does Jasper Therapeutics, Inc. do?
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutic agents for hematopoietic stem cell transplantation and gene therapies. Their lead product candidate, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. The company is also developing engineered hematopoietic stem cells to overcome limitations of current stem cell grafts, aiming to improve patient outcomes in transplantation and gene therapy.
What do analysts say about JSPR stock?
As of 2026, analyst coverage of Jasper Therapeutics, Inc. (JSPR) is limited given its market capitalization of $7.72M. However, analysts generally recognize the potential of JSP191 as a conditioning antibody in stem cell transplantation and gene therapy. Key valuation metrics are heavily influenced by the clinical trial outcomes of JSP191. Growth considerations include successful regulatory approvals and the ability to secure partnerships for commercialization. Analyst opinions are subject to change based on clinical data and market developments.
What are the main risks for JSPR?
The main risks for Jasper Therapeutics, Inc. include the potential for clinical trial failures of JSP191, which could significantly impact the company's value. Regulatory delays or non-approval of JSP191 also pose a significant risk. Competition from established pharmaceutical companies and other biotechnology firms developing similar therapies could limit market share. The company's high cash burn rate and need for additional financing could dilute existing shareholders. Dependence on key personnel and intellectual property also presents risks.
What are the key factors to evaluate for JSPR?
Jasper Therapeutics, Inc. (JSPR) holds an AI score of 27/100 (low). Analysts target $3.00 (+531%). Not financial advice.
How frequently does JSPR data refresh on this page?
JSPR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven JSPR's recent stock price performance?
Jasper Therapeutics, Inc. (JSPR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform for stem cell engineering. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider JSPR overvalued or undervalued right now?
Valuing Jasper Therapeutics, Inc. (JSPR) requires multiple metrics. Analysts target $3.00 (+531%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying JSPR?
Before investing in Jasper Therapeutics, Inc. (JSPR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- Clinical trial outcomes are inherently uncertain.